The concept of activating benefit recipients into work has become an important building block in OECD and EU countries' strategies to fight high unemployment.
However, while it has worked very well for activating unemployment benefit recipients and more recently for activating sole parents with young children, the quasi-market system has been much less successful in terms of activating disability benefit recipients.
In sum, the OECD's activation reviews have highlighted examples of both success in terms of activating UI benefit recipients (Australia, Japan, Norway, Switzerland, UK) and failures, at least until recently (Finland, Ireland).
OECD (2013c) points out that it has proved hard to transfer the success achieved in activating UI benefit recipients to disability benefit recipients.
Finally, it has proved very difficult to transfer success in activating UI benefit recipients to other recipients of inactive benefits, notably those in receipt of long-term sickness/disability benefits.
However, patients with EGFR-activating mutations benefit from treatment with EGFR-TKIs (e.g., gefitinb and erlotinib) for less than approximately 1 year, after which drug resistance develops.
She understands exactly when she can activate activism for her own benefit.
For OMT to be activated, the benefited country needs to ask for a bailout from the ESM.
We would like to emphasize that we are not arguing for a complete elimination of explicit assessments such as multiple-choice tests which have their own advantages for learning such as testing effects (the memory retrieval processes activated during testing benefit long-term memory of the target material; (Roediger and Karpicke 2006)).
However, not all patients carrying activating mutant EGFR benefit from TKI therapy and almost all acquire resistance within a year after initial response (Haber et al, 2005; Riely et al, 2006; Sharma et al, 2007).
Therefore, understanding of the TLR9 signaling pathway will shed light on how the immune response is activated and will benefit the development of specific therapies that can efficiently fight against cancer and infectious diseases.
